Abstract
Important roles have been suggested for caspase-8, caspase-9 and Apaf-1 in controlling tumor development and their sensitivity to chemotherapeutic agents. Methylation and deletion of Apaf-1 and CASP8 results in the loss of their expression in melanoma and neuroblastoma, respectively, while CASP9 localization to 1p36.1 suggests it is a good candidate tumor suppressor. The status of CASP9 and Apaf-1 expression in numerous neuroblastoma cell lines with/without amplified MYCN and chromosome 1p36 loss-of-heterozygosity (LOH) was therefore examined to test the hypothesis that one or both of these genes are tumor suppressors in neuroblastoma. Although CASP9 is included in the region encompassing 1p36 LOH in all neuroblastoma cell lines examined, the remaining CASP9 allele(s) express a functional caspase-9 enzyme. Apaf-1 is also expressed in all neuroblastoma tumor cell lines examined. Thus, the CASP9 or Apaf-1 genes do not appear to function as tumor suppressors in MYCN amplified neuroblastomas. However, ∼20% of the neuroblastoma cell lines with methylated CASP8 alleles are also highly resistant to staurosporine (STS)- and radiation-induced cell death, presumably because cytochrome c is not released from mitochondria. This suggests that a second, smaller sub-group of MYCN amplified neuroblastoma tumors exists with defect(s) in apoptotic signaling components upstream of caspase-9 and Apaf-1. Since no consistent differences in Bcl-2, Bcl-xL or Bax expression were seen in the STS- and radiation-resistant neuroblastomas, it suggests that a unique mitochondrial signaling factor(s) is responsible for the defect in cytochrome c release in this sub-group of tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Asselin E, Mills GB, Tsang BK . 2001 Cancer Res. 61: 1862–1868
Bala S, Oliver H, Renault B, Montgomery K, Dutta S, Rao P, Houldsworth J, Kucherlapati R, Wang XD, Chaganti R, Murty VVVS . 2000 Genes, Chromosomes Cancer 28: 258–268
Belka C, Rudner J, Wesselborg S, Stepczynska A, Marini P, Lepple-Weinhues A, Faltin H, Bamberg M, Budach W, Schulze-Osthoff K . 2000 Oncogene 19: 1181–1190
Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y . 1994 Exp. Cell Res. 211: 314–321
Brodeur GM, Azar C, Brother M, Hiemstra JL, Kaurman B, Marshall H, Moley J, Nakagawara A, Saylors R, Scavard N, Schneider S, Wasson J, White P, Seeger R, Look AT, Castleberry RP . 1992 Cancer 70: 1685–1694
Caron H . 1995 Med. Ped. Oncol. 24: 215–221
Caron HN, van Sluis P, van Hoeve M, de Kraker J, Bras J, Slater R, Mannens M, Voute PA, Westerveld A, Versteeg R . 1993 Nature Gen. 4: 187–190
Chen X, Ko LJ, Prives C . 1996 Genes Dev. 10: 2438–2451
Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, Larochette N, Prevost MC, Leber B, Andrews D, Penninger J, Kroemer G . 2000 FASEB J. 14: 729–739
Du C, Fang M, Li Y, Li L, Wang X . 2000 Cell 102: 33–42
Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, Brodeur GM . 2001 Cancer Res. 61: 1314–1319
Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, Wajant H, Janicke RU, Porter AG, Belka C, Gregor M, Schulze-Osthoff K, Wesselborg S . 2000 Oncogene 19: 4563–4573
Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G . 2000 Cancer Res. 60: 7133–7141
Gastman BR, Yin XM, Johnson DE, Wieckowski E, Wang GQ, Watkins SC, Rabinowich H . 2000 Cancer Res. 60: 6811–6817
Gross A, McDonnell JM, Korsmeyer SJ . 1999a Genes Dev. 13: 1899–1911
Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P, Korsmeyer SJ . 1999b J. Biol. Chem. 274: 1156–1163
Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur GM, Phillips PC . 2000 Oncogene 19: 4604–4610
Gu Y, Sarnecki C, Aldape RA, Livingston DJ, Su MS-S . 1995 J. Biol. Chem. 270: 18715–18718
Juin P, Hueber AO, Littlewood T, Evan GI . 1999 Genes Dev. 13: 1367–1381
Kennedy SG, Kandel ES, Cross TK, Hay N . 1999 Mol. Cell. Biol. 19: 5800–5810
Knudson AG, Meadows AT . 1980 N. Engl. J. Med. 302: 1254–1256
Kuida K, Haydar TF, Kuan C-Y, Gu Y, Taya C, Karasuyama H, Su MS-S, Rakic P, Flavell RA . 1998 Cell 94: 325–337
Kuwana T, Smith JJ, Muzio M, Dixit VM, Newmeyer DD, Kornbluth S . 1998 J. Biol. Chem. 273: 16589–16594
LaBonne C, Bronner-Fraser M . 1999 Annu. Rev. Cell Dev. Biol. 15: 81–112
Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT . 2001 Cancer Res. 61: 1645–1651
Lowe SW, Ruley HE, Jacks T, Housman DE . 1993 Cell 74: 957–967
Reed JC . 1997 Nature 387: 773–776
Saleh A, Srinivasula SM, Acharya S, Fishel R, Alnemri ES . 1999 J. Biol. Chem. 274: 17941–17945
Scaffidi C, Medema JP, Krammer PH, Peter ME . 1997 J. Biol. Chem. 272: 26953–26958
Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR . 2000 J. Biol. Chem. 275: 7337–7342
Shimizu S, Matsuoka Y, Shinohara Y, Yoneda Y, Tsujimoto Y . 2001 J. Cell Biol. 152: 237–250
Slee EA, Keogh SA, Martin SJ . 2000 Cell Death Differ. 7: 556–565
Soengas MS, Alarc Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW . 1999 Science 284: 156–159
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW . 2001 Nature 409: 207–211
Stegh AH, Herrmann H, Lampel S, Weisenberger D, Andra K, Seper M, Wiche G, Krammer PH, Peter ME . 2000 Mol. Cell. Biol. 20: 5665–5679
Stennicke HR, Deveraux QL, Humke EW, Reed JC, Dixit VM, Salveson GS . 1999 J. Biol. Chem. 274: 8359–8362
Takita J, Yang HW, Chen YY, Hanada R, Yamamoto K, Teitz T, Kidd VJ, Hayashi Y . 2001 Oncogene 20: 4424–4432
Tang D, Lahti JM, Grenet J, Kidd VJ . 1999 J. Biol. Chem. 274: 7245–7252
Tang D, Lahti JM, Kidd VJ . 2000 J. Biol. Chem. 275: 9303–9307
Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ . 2000 Nature Med. 6: 529–535
Tweddle DA, Malcolm AJ, Bown N, Pearson ADJ, Lunec J . 2001 Cancer Res. 61: 8–13
Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL . 2000 Cell 102: 43–53
Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ . 2000 Science 290: 1761–1765
Zhang H, Xu Q, Krajewski S, Krajewska M, Xie Z, Fuess S, Kitada S, Godzik A, Reed JC . 2000 Proc. Natl. Acad. Sci., USA 97: 2597–2602
Zhou H, Li X-M, Meinkoth J, Pittman RN . 2000 J. Cell Biol. 151: 483–494
Acknowledgements
This work was supported by a grant from the NIH (5 RO1 CA67938) to VJ Kidd, by a Cancer Center Support Grant (5 PO1 CA21765) awarded to St Jude Children's Research Hospital, and by the generous support of the American Lebanese Syrian Associated Charities (ALSAC). Dr Xiaodang Wang kindly provided the human caspase-9 polyclonal antiserum.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Teitz, T., Wei, T., Liu, D. et al. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Oncogene 21, 1848–1858 (2002). https://doi.org/10.1038/sj.onc.1205180
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205180
Keywords
This article is cited by
-
Identification of BIRC6 as a novel intervention target for neuroblastoma therapy
BMC Cancer (2012)
-
Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules
Oncogene (2009)
-
Potentiation of neuroblastoma metastasis by loss of caspase-8
Nature (2006)
-
Insulin-like growth factor-I regulates glucose-induced mitochondrial depolarization and apoptosis in human neuroblastoma
Cell Death & Differentiation (2004)